Abstract 1360TiP
Background
Pembro (programmed death protein 1 [PD-1] inhibitor) ± platinum (Pt)-based chemotherapy (CT), with pembro maintained until progression, is a standard 1L treatment for advanced/metastatic NSCLC. However, durable long-term benefit is limited to a small subset of patients. Nira, a poly(ADP-ribose) polymerase inhibitor (PARPi), promotes PARP trapping, activates the STING pathway, recruits T cells, and upregulates PD-L1, making it a promising partner for PD-1 inhibitors. Nira crosses the blood–brain barrier in animal models with 34-fold higher brain tissue exposure than other PARPi, suggesting it may reduce risk/progression of brain metastasis (BM). Nira + pembro has shown antitumour activity and acceptable safety in triple-negative breast cancer and Pt-resistant ovarian cancer (TOPACIO/KEYNOTE-162), and as 1L therapy in advanced/metastatic NSCLC (JASPER).
Trial design
ZEAL-1L (NCT04475939) is a phase III, randomised, double-blind trial comparing efficacy and safety of 1L maintenance therapy with oral nira (200/300 mg/day) + intravenous pembro (200 mg on Day 1 of each 21-day cycle; maximum 35 cycles from start of 1L induction CT) versus placebo + pembro in adults with histologically/cytologically confirmed Stage IIIB–IV NSCLC without known driver mutations and with stable disease or partial/complete response to 4–6 cycles of 1L Pt-based induction CT + pembro. Patients with asymptomatic BM (i.e. off corticosteroids and anticonvulsants for ≥7 days) are permitted. Approximately 650 patients will be randomised (1:1), with stratification by histology, PD-L1 status and response to 1L induction CT + pembro. Treatment will continue until disease progression (PD), unacceptable toxicity, death, or loss to follow-up. Imaging occurs every 6 weeks (Q6W) for 48 weeks/until PD, and Q12W for patients still on treatment thereafter. Primary endpoints are PFS and OS. Time to central nervous system progression is a key secondary endpoint; others include investigator-assessed PFS, PFS and OS by PD-L1 status, quality of life, safety and pharmacokinetics. Exploratory analyses are also planned. Enrolment began November 2020.
Clinical trial identification
NCT04475939.
Editorial acknowledgement
Medical writing support was provided by Nadia Hashash, PhD, of Core Medica, London, UK, funded by GlaxoSmithKline.
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline (ID: 213400).
Disclosure
S.S. Ramalingam: Financial Interests, Personal, Other, Consultancy fees: Amgen; Financial Interests, Personal, Other, Consultancy fees: AbbVie; Financial Interests, Personal, Other, Consultancy fees: AstraZeneca; Financial Interests, Personal, Other, Consultancy fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Consultancy fees: Genentech/F. Hoffmann-La Roche; Financial Interests, Personal, Other, Consultancy fees: Merck; Financial Interests, Personal, Research Grant: Amgen; Financial Interests, Personal, Research Grant: Advaxis; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Merck; Financial Interests, Personal, Research Grant: Takeda; Financial Interests, Personal, Research Grant: Tesaro (a GlaxoSmithKline company). G. de Castro Jr.: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Teva; Financial Interests, Personal, Advisory Board: Yuhan; Financial Interests, Personal, Other, Consultancy fees or personal fees: AstraZeneca; Financial Interests, Personal, Other, Consultancy fees or personal fees: Bayer; Financial Interests, Personal, Other, Consultancy fees or personal fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Consultancy fees or personal fees: Boehringer Ingelheim; Financial Interests, Personal, Other, Consultancy fees or personal fees: Janssen; Financial Interests, Personal, Other, Consultancy fees or personal fees: Lilly; Financial Interests, Personal, Other, Consultancy fees or personal fees: Merck Serono; Financial Interests, Personal, Other, Consultancy fees or personal fees: Merck Sharp & Dohme; Financial Interests, Personal, Other, Consultancy fees or personal fees: Novartis; Financial Interests, Personal, Other, Consultancy fees or personal fees: Pfizer; Financial Interests, Personal, Other, Consultancy fees or personal fees: Roche; Financial Interests, Personal, Other, Consultancy fees or personal fees: Teva; Financial Interests, Personal, Other, Consultancy fees or personal fees: Yuhan. M.C.C. Garassino: Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Amgen; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: AstraZeneca/MedImmune; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Bayer Healthcare Pharmaceuticals; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Blueprint Medicines; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Celgene; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Daiichi Sankyo; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Eli Lilly; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Exelixis; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: GlaxoSmithKline; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Incyte; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Inivata; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Ipsen; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Janssen; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: MedImmune; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Merck Sharp & Dohme; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: MSD Oncology; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Novartis; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Otsuka; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Pfizer; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Regeneron; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Roche/Genentech; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Sanofi-Aventis; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Seattle Genetics; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Spectrum Pharmaceuticals; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Tiziana Life Sciences; Financial Interests, Personal, Other, Speakers’ Honoraria, Consultancy, and Advisory fees: Takeda. J. Mazieres: Financial Interests, Personal, Research Grant, Honoraria: Amgen; Financial Interests, Personal, Research Grant, Honoraria: AstraZeneca; Financial Interests, Personal, Research Grant, Honoraria: Blueprint Medicines; Financial Interests, Personal, Research Grant, Honoraria: Bristol Myers Squibb; Financial Interests, Personal, Research Grant, Honoraria: Daiichi Sankyo; Financial Interests, Personal, Research Grant, Honoraria: Hengrui; Financial Interests, Personal, Research Grant, Honoraria: Merck Sharp & Dohme; Financial Interests, Personal, Research Grant, Honoraria: Novartis; Financial Interests, Personal, Research Grant, Honoraria: Pierre Fabre; Financial Interests, Personal, Research Grant, Honoraria: Roche; Financial Interests, Personal, Research Grant: Takeda. R.E. Sanborn: Financial Interests, Personal, Research Grant, Honoraria, Research support: Amgen; Financial Interests, Personal, Research Grant, Honoraria, Research support: AstraZeneca; Financial Interests, Personal, Research Grant, Honoraria, Research support: Blueprint Medicines; Financial Interests, Personal, Research Grant, Honoraria, Research support: Bristol Myers Squibb; Financial Interests, Personal, Research Grant, Honoraria, Research support: Daiichi Sankyo; Financial Interests, Personal, Research Grant, Honoraria, Research support: Lilly; Financial Interests, Personal, Research Grant, Honoraria, Research support: EMD Serono; Financial Interests, Personal, Research Grant, Honoraria, Research support: Janssen Oncology; Financial Interests, Personal, Research Grant, Honoraria, Research support: MedImmune; Financial Interests, Personal, Research Grant, Honoraria, Research support: Merck; Financial Interests, Personal, Research Grant, Honoraria, Research support: Roche/Genentech; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Amgen; Financial Interests, Personal, Advisory Role, Consulting/advisory role fees: Amgen; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Blueprint Medicines; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Daiichi Sankyo; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Lilly; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: EMD Serono; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Janssen Oncology; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: MedImmune; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Merck; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Roche/Genentech. E.F.F. Smit: Financial Interests, Personal, Sponsor/Funding, Research funding: AstraZeneca; Financial Interests, Personal, Sponsor/Funding, Research funding: Bayer; Financial Interests, Personal, Sponsor/Funding, Research funding: Daiichi Sankyo; Financial Interests, Personal, Sponsor/Funding, Research funding: Lilly; Financial Interests, Personal, Sponsor/Funding, Research funding: Boehringer Ingelheim; Financial Interests, Personal, Sponsor/Funding, Research funding: Bristol Myers Squibb; Financial Interests, Personal, Sponsor/Funding, Research funding: Merck KGaA; Financial Interests, Personal, Sponsor/Funding, Research funding: MSD Oncology; Financial Interests, Personal, Sponsor/Funding, Research funding: Novartis; Financial Interests, Personal, Sponsor/Funding, Research funding: Roche/Genentech; Financial Interests, Personal, Sponsor/Funding, Research funding: Seattle Genetics; Financial Interests, Personal, Sponsor/Funding, Research funding: Takeda; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: AstraZeneca; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Bayer; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Daiichi Sankyo; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Lilly; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Boehringer Ingelheim; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Merck KGaA; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: MSD Oncology; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Novartis; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Roche/Genentech; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Seattle Genetics; Financial Interests, Personal, Advisory Role, Consulting/Advisory Role fees: Takeda. D.R. Spigel: Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Aeglea Biotherapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Agios; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Amgen; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Apitude Health; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Apollomics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Astellas Pharma; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: AstraZeneca; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Bayer; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: BIND Therapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Calithera Biosciences; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Celgene; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Celldex; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Clovis Oncology; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Curio Science; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Cyteir; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Daiichi Sankyo; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Dracen; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Eisai; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Elevation Oncology; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: EMD Serono; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Evelo Therapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Exelixis; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Genentech/Roche; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: GlaxoSmithKline; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: GRAIL; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: G1 Therapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Iksuda Therapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Illumina; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: ImClone Systems; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Immunogen; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Intellisphere; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Ipsen; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Janssen Oncology; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Jazz Pharmaceuticals; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Lilly; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: MedImmune; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Merck; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Molecular Partners; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Molecular Templates; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Mirati Therapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Nektar; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Neon Therapeutics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Novartis; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Novocure; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Pfizer; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: PharmaMar; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Puma Biotechnology; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Regeneron; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Roche/Genentech; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Sanofi-Aventis; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Seattle Genetics; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Takeda; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Tesaro; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Transgene; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: Triptych Health Partners; Financial Interests, Personal, Other, Consulting, Advisory Role, Research Funding and Travel fees: TRM Oncology. M. Thomas: Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: AbbVie; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: AstraZeneca; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Bristol Myers Squibb; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Boehringer Ingelheim; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Celgene; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Chugai; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role Fees, Research Funding and Travel Support: Lilly; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and advisory role fees, Research Funding and Travel Support: Merck Sharp & Dohme; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Novartis; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Pfizer; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Roche; Financial Interests, Personal, Other, Speaker Honoraria, Consulting and Advisory Role fees, Research Funding and Travel Support: Takeda. V. Velcheti: Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Alkermes; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Altor Bioscience; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Altreca; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: AstraZeneca/MedImmune; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Boston Scientific; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Bristol Myers Squibb; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Eisai; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: EMD Serono; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Genentech; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Genoptix; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: GlaxoSmithKline; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Heat Biologics; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Leap Therapeutics; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Merck; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Foundation Medicine; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Lilly; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Nantworks; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Novartis; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Novocure; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: OncoPlex Diagnostics; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: RSIP Vision; Financial Interests, Personal, Other, Consulting and Advisory Role fees and Research Funding: Trovagene. E. Zhi: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline; Financial Interests, Personal, Ownership Interest: GlaxoSmithKline. M. Whipple Neibauer: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline; Financial Interests, Personal, Ownership Interest: GlaxoSmithKline; Financial Interests, Personal, Ownership Interest: Merck. A. Stojadinovic: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline; Financial Interests, Personal, Ownership Interest: GlaxoSmithKline. S. Peters: Consultation / Advisory role: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Bio Invent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, Merck Sharp & Dohme, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar, Phosplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody Talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, Merck Sharp & Dohme, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda. Receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, F. Hoffmann-La Roche/Genentech, GSK, Illumina, Lilly, Merck Sharp & Dohme, Merck Serono, Mirati, Novartis, and Pfizer, Phosplatin Therapeutics.